Filter Results:
(112)
Show Results For
- All HBS Web
(112)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Show Results For
- All HBS Web
(112)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
- December 1997 (Revised October 2006)
- Case
Merck Sharp & Dohme Argentina, Inc. (A)
By: Lynn S. Paine and Hal Hogan
Describes the efforts of the new managing director of Merck's subsidiary for Argentina, Uruguay, and Paraguay to transform the organization and its culture. Focuses on a critical decision: whether to offer the son of a high-ranking official in the government's national... View Details
Keywords: Business or Company Management; Ethics; Decision Making; Organizational Change and Adaptation; Organizational Culture; Leadership; Cross-Cultural and Cross-Border Issues; Conflict of Interests; Argentina; Uruguay; Paraguay
Paine, Lynn S., and Hal Hogan. "Merck Sharp & Dohme Argentina, Inc. (A)." Harvard Business School Case 398-033, December 1997. (Revised October 2006.)
- January 2018
- Case
Merck CEO Ken Frazier Quits President Trump's Advisory Council
By: Andy Zelleke and Brian Tilley
In the first six months of Donald Trump’s presidency, Merck CEO Kenneth Frazier appeared alongside Trump at least three times at press events, one of which commemorated the first and only meeting of the president’s Manufacturing Job Initiative (better known at the... View Details
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
- June 2003
- Teaching Note
Discovering the Future: R&D Strategy at Merck (TN)
By: Gary P. Pisano
Teaching Note for (9-601-086). View Details
Keywords: Pharmaceutical Industry
- June 2001
- Supplement
Merck & Company: Evaluating a Drug Licensing Opportunity
Spreadsheet to (9-201-023). Download only. View Details
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- November 2004
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B)
By: Lynn S. Paine
Teaching Note to (9-398-033) and (9-398-034). View Details
- September 2001 (Revised October 2001)
- Teaching Note
Merck & Company: Evaluating A Drug Licensing Opportunity TN
By: Richard S. Ruback and Aldo Sesia
Teaching Note for (9-201-023). View Details
Keywords: Service Industry
- August 1994 (Revised March 1995)
- Supplement
Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)
Supplements the (A) case. View Details
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)." Harvard Business School Supplement 395-035, August 1994. (Revised March 1995.)
- January 1999 (Revised March 1999)
- Case
Merck & Co., Inc.: Corporate Strategy, Organization and Culture (B)
By: Michael Beer and James Weber
Supplements the (A) case. View Details
Keywords: United States
Beer, Michael, and James Weber. "Merck & Co., Inc.: Corporate Strategy, Organization and Culture (B)." Harvard Business School Case 499-046, January 1999. (Revised March 1999.)
- January 1994
- Case
Evolving Finance Function: Judy C. Lewent at Merck & Co., Inc.
By: Timothy A. Luehrman
This case examines the career path of Merck's CFO, Judy C. Lewent, as a way of tracing changes over time in Merck's finance function. It describes the adoption of innovative quantitative analytical models, changes in job definitions and in the organization of the... View Details
Keywords: Finance; Mathematical Methods; Personal Development and Career; Organizational Design; Innovation and Invention; Pharmaceutical Industry
Luehrman, Timothy A. "Evolving Finance Function: Judy C. Lewent at Merck & Co., Inc." Harvard Business School Case 294-014, January 1994.
- October 2006
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)
By: Lynn S. Paine
Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk
VIDEO: Ken Frazier, one of only four Black CEOs of Fortune 500 companies, speaks with Professor Tsedal Neeley about the search for a coronavirus vaccine, how racism at the workplace holds back America’s progress, and his own... View Details
- April 1995
- Teaching Note
Evolving Finance Function, The: Judy C. Lewent at Merck & Co., Inc. (TN)
By: Timothy A. Luehrman
Teaching Note for (9-294-014). View Details
Keywords: Pharmaceutical Industry
- March 2013
- Teaching Note
Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)
By: David J. Collis
- August 2013
- Teaching Plan
Remicade-Simponi
By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
Keywords: Johnson & Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry
Subramanian, Guhan, and Charlotte Krontiris. "Remicade-Simponi." Harvard Business School Teaching Plan 914-006, August 2013.
- 14 Jul 2020
- Podcast
Special Episode: Tsedal Neeley and Merck CEO Ken Frazier on vaccines, racism, and leadership
Merck Chairman and CEO, Ken Frazier—one of only four Black CEOs in the Fortune 500—joins HBS Professor Tsedal Neeley. Topics include the necessity of putting science ahead of politics in the search for a cure for Covid-19 and steps corporate leaders need to take if... View Details
- 01 Jun 2004
- News
Merck’s Gilmartin on Vaccines, Global Health
Viruses are out there, waiting to strike, and vaccinations are our best defense. But that defense is a man-made system, and therefore subject to breakdowns. In a talk titled “The Significance of Vaccines in Global Health,” Merck CEO... View Details